Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study

Kun Liu, Hanying Wang, Wei He, Jian Ye, Yanping Song, Yusheng Wang, Xiaoling Liu, Zhifeng Wu, Shaojun Chen, Ke Fan, Yuling Liu, Feng Zhang, Zhiqing Li, Lin Liu, Junjun Zhang, Xuedong Zhang, Junjie Ye, Xiaoling Liang, Xiaoxin Li, Xiao Ke, Quan Wu, Jie Li, Shanshan Tao, Xinguo Wang, Philip Rosenfeld, Jeffrey S Heier, Peter Kaiser, Xun Xu, Kun Liu, Hanying Wang, Wei He, Jian Ye, Yanping Song, Yusheng Wang, Xiaoling Liu, Zhifeng Wu, Shaojun Chen, Ke Fan, Yuling Liu, Feng Zhang, Zhiqing Li, Lin Liu, Junjun Zhang, Xuedong Zhang, Junjie Ye, Xiaoling Liang, Xiaoxin Li, Xiao Ke, Quan Wu, Jie Li, Shanshan Tao, Xinguo Wang, Philip Rosenfeld, Jeffrey S Heier, Peter Kaiser, Xun Xu

Abstract

Background: To demonstrate the efficacy and safety of intravitreal injections of conbercept versus laser photocoagulation in the treatment of diabetic macular oedema (DME).

Methods: A 12-month multicentre, randomised, double-masked, double-sham, parallel controlled, phase III trial (Sailing Study), followed by a 12-month open-label extension study. Patients with centre-involved DME were randomly assigned to receive either laser photocoagulation followed by pro re nata (PRN) sham intravitreal injections (laser/sham) or sham laser photocoagulation followed by PRN 0.5 mg conbercept intravitreal injections (sham/conbercept). Patients who entered the extension study received PRN conbercept treatment. The primary endpoint was the changes in best-corrected visual acuity (BCVA) from baseline.

Results: A total of 248 eyes were included in the full analysis set and 157 eyes continued in the extension study. Significant improvement in mean change in BCVA from baseline to month 12 was observed in the sham/conbercept group (8.2±9.5 letters), whereas no improvement was observed in the laser/sham group (0.3±12.0 letters). Patients in the laser/sham group showed a marked improvement in BCVA after the switch to conbercept in the extension study, and there was no difference in BCVA between the two groups at the end of the extension study.

Conclusion: The use of a conbercept PRN intravitreal injection regimen improved the BCVA of patients with DME, and its efficacy was better than that of laser photocoagulations, and the same efficacy was observed when the eyes treated with laser alone were switched to conbercept.

Trial registration number: NCT02194634.

Keywords: clinical trial; macula; retina; treatment lasers.

Conflict of interest statement

Competing interests: XK, QW, JL, ST and XW are employees of Chengdu Kanghong Biotechnology, Company, Ltd. PR and PK are consultants to Chengdu Kanghong Biotech.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flowchart.
Figure 2
Figure 2
Mean changes in BCVA for laser and conbercept study groups in the Sailing Study. (A) One-year results compared with baseline. (B) Two-year results compared with baseline for the subset of eyes that continued in the extension study. Error bars denote SD. BCVA, best-corrected visual acuity.
Figure 3
Figure 3
Mean changes of secondary endpoints for laser and conbercept study groups in the Sailing Study. (A) One-year results of mean CRT changes compared with baseline. (B) Extension study results of mean CRT changes from 12 to 24 months. (C) Mean changes in TMV compared with baseline (1-year results). (D) Mean changes in TMV from 12 to 24 months (extension study results). (E) Mean change in NEI VFQ-25 total score from baseline to month 12 of the Sailing Study. Error bars denote SD. CRT, central retinal thickness; NEI VEQ-25, 25-Item National Eye Institute Visual Function Questionnaire; TMV, total macular volume.

References

    1. American Diabetes Association . 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42:S124–38. 10.2337/dc19-S011
    1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124–36.
    1. Wong TY, Sun J, Kawasaki R, et al. . Guidelines on diabetic eye care: the International Council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology 2018;125:1608–22. 10.1016/j.ophtha.2018.04.007
    1. Yau JWY, Rogers SL, Kawasaki R, et al. . Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–64. 10.2337/dc11-1909
    1. Sivaprasad S, Gupta B, Gulliford MC, et al. . Ethnic variations in the prevalence of diabetic retinopathy in people with diabetes attending screening in the United Kingdom (drive UK). PLoS One 2012;7:e32182. 10.1371/journal.pone.0032182
    1. Sivaprasad S, Gupta B, Crosby-Nwaobi R, et al. . Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol 2012;57:347–70. 10.1016/j.survophthal.2012.01.004
    1. Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management. Indian J Ophthalmol 2018;66:1736–50. 10.4103/ijo.IJO_1240_18
    1. Shah CP, Chen C. Review of therapeutic advances in diabetic retinopathy. Ther Adv Endocrinol Metab 2011;2:39–53. 10.1177/2042018810396750
    1. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76. 10.1038/nm0603-669
    1. Spilsbury K, Garrett KL, Shen WY, et al. . Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000;157:135–44. 10.1016/S0002-9440(10)64525-7
    1. van Lookeren Campagne M, LeCouter J, Yaspan BL, et al. . Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol 2014;232:151–64. 10.1002/path.4266
    1. Homayouni M. Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. J Ophthalmic Vis Res 2009;4:105–14.
    1. Solomon SD, Lindsley K, Vedula SS, et al. . Anti-Vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2019;3:CD005139. 10.1002/14651858.CD005139.pub4
    1. Ollendorf DA, Colby JA, Pearson SD. Comparative effectiveness of anti-VEGF agents for diabetic macular edema. Int J Technol Assess Health Care 2013;29:392–401. 10.1017/S0266462313000500
    1. Korobelnik J-F, Do DV, Schmidt-Erfurth U, et al. . Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247–54. 10.1016/j.ophtha.2014.05.006
    1. Brown DM, Schmidt-Erfurth U, Do DV, et al. . Intravitreal aflibercept for diabetic macular edema: 100-Week results from the VISTA and vivid studies. Ophthalmology 2015;122:2044–52. 10.1016/j.ophtha.2015.06.017
    1. Heier JS, Korobelnik J-F, Brown DM, et al. . Intravitreal aflibercept for diabetic macular edema: 148-Week results from the VISTA and vivid studies. Ophthalmology 2016;123:2376–85. 10.1016/j.ophtha.2016.07.032
    1. Zhang J, Liang Y, Xie J, et al. . Conbercept for patients with age-related macular degeneration: a systematic review. BMC Ophthalmol 2018;18:142. 10.1186/s12886-018-0807-1
    1. Nguyen QD, Brown DM, Marcus DM, et al. . Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: rise and ride. Ophthalmology 2012;119:789–801. 10.1016/j.ophtha.2011.12.039
    1. Wang Q, Li T, Wu Z, et al. . Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo. PLoS One 2013;8:e70544. 10.1371/journal.pone.0070544
    1. Li H, Lei N, Zhang M, et al. . Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 2012;97:154–9. 10.1016/j.exer.2011.09.002
    1. Bressler SB, Beaulieu WT, Glassman AR, et al. . Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: factors associated with vision and edema outcomes. Ophthalmology 2018;125:1776–83. 10.1016/j.ophtha.2018.04.039
    1. Schmidt-Erfurth U, Lang GE, Holz FG, et al. . Three-Year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the restore extension study. Ophthalmology 2014;121:1045–53. 10.1016/j.ophtha.2013.11.041
    1. Liu K, Song Y, Xu G, et al. . Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 Phoenix study. Am J Ophthalmol 2019;197:156–67. 10.1016/j.ajo.2018.08.026
    1. Sun Z, Zhou H, Lin B, et al. . Efficacy and safety of intravitreal CONBERCEPT injections in macular edema secondary to retinal vein occlusion. Retina 2017;37:1723–30. 10.1097/IAE.0000000000001404
    1. Diabetic Retinopathy Clinical Research Network* . Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013;131:283–93. 10.1001/jamaophthalmol.2013.2015
    1. Ahn J, Woo SJ, Chung H, et al. . The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology 2011;118:2218–26. 10.1016/j.ophtha.2011.03.036
    1. Googe J, Brucker AJ, Diabetic Retinopathy Clinical Research Network, et al. . Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009–27. 10.1097/IAE.0b013e318217d739
    1. Daien V, Nguyen V, Essex RW, et al. . Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology 2018;125:66–74. 10.1016/j.ophtha.2017.07.005

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner